Acurx Pharmaceuticals/$ACXP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Acurx Pharmaceuticals
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
- Ticker
- $ACXP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Staten Island, United States
- Website
- www.acurxpharma.com
ACXP Metrics
BasicAdvanced
$5.4M
-
-$2.78
-2.03
-
Price and volume
Market cap
$5.4M
Beta
-2.03
52-week high
$7.54
52-week low
$0.95
Average daily volume
87K
Financial strength
Current ratio
3.878
Quick ratio
3.796
Profitability
Management effectiveness
Return on assets (TTM)
-55.92%
Return on equity (TTM)
-128.11%
Valuation
Price to book
0.59
Price to tangible book (TTM)
0.59
Price to free cash flow (TTM)
-0.449
Free cash flow yield (TTM)
-222.58%
Free cash flow per share (TTM)
-2.293
Growth
Earnings per share change (TTM)
-73.15%
3-year earnings per share growth (CAGR)
-50.23%
ACXP Financial Performance
Revenues and expenses
ACXP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.